Of note, this study is one of the largest studies analyzing CTNNB1 mutations in EGFR-mutated NSCLC and, to our knowledge, the first one that systematically investigates the response to EGFR-TKIs in first-line therapy. Here, CTNNB1 is linked to non-small cell lung carcinoma.